Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
Veru Inc.: Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...